换一批Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
第一作者：
Karolin,Heinze
第一单位：
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.;University of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.
作者：
Karolin,Heinze [1]
;
Tayyebeh M,Nazeran [2]
;
Sandra,Lee [3]
;
Pauline,Krämer [4]
;
Evan S,Cairns [5]
;
Derek S,Chiu [2]
;
Samuel Cy,Leung [2]
;
Eun Young,Kang [3]
;
Nicola S,Meagher [6]
;
Catherine J,Kennedy [7]
;
Jessica,Boros [7]
;
Friedrich,Kommoss [8]
;
Hans-Walter,Vollert [9]
;
Florian,Heitz [10]
;
Andreas,du Bois [10]
;
Philipp,Harter [10]
;
Marcel,Grube [4]
;
Bernhard,Kraemer [11]
;
Annette,Staebler [12]
;
Felix Kf,Kommoss [13]
;
Sabine,Heublein [14]
;
Hans-Peter,Sinn [13]
;
Naveena,Singh [15]
;
Angela,Laslavic [16]
;
Esther,Elishaev [17]
;
Alex,Olawaiye [16]
;
Kirsten,Moysich [18]
;
Francesmary,Modugno [16]
;
Raghwa,Sharma [19]
;
Alison H,Brand [20]
;
Paul R,Harnett [21]
;
Anna,DeFazio [22]
;
Renée T,Fortner [23]
;
Jan,Lubinski [24]
;
Marcin,Lener [24]
;
Aleksandra,Tołoczko-Grabarek [24]
;
Cezary,Cybulski [24]
;
Helena,Gronwald [25]
;
Jacek,Gronwald [24]
;
Penny,Coulson [26]
;
Mona A,El-Bahrawy [27]
;
Michael E,Jones [26]
;
Minouk J,Schoemaker [26]
;
Anthony J,Swerdlow [28]
;
Kylie L,Gorringe [29]
;
Ian,Campbell [30]
;
Linda,Cook [31]
;
Simon A,Gayther [32]
;
Michael E,Carney [33]
;
Yurii B,Shvetsov [34]
;
Brenda Y,Hernandez [34]
;
Lynne R,Wilkens [34]
;
Marc T,Goodman [35]
;
Constantina,Mateoiu [36]
;
Anna,Linder [36]
;
Karin,Sundfeldt [36]
;
Linda E,Kelemen [37]
;
Aleksandra,Gentry-Maharaj [38]
;
Martin,Widschwendter [39]
;
Usha,Menon [40]
;
Kelly L,Bolton [41]
;
Jennifer,Alsop [42]
;
Mitul,Shah [43]
;
Mercedes,Jimenez-Linan [43]
;
Paul Dp,Pharoah [44]
;
James D,Brenton [45]
;
Kara L,Cushing-Haugen [46]
;
Holly R,Harris [46]
;
Jennifer A,Doherty [47]
;
Blake,Gilks [2]
;
Prafull,Ghatage [48]
;
David G,Huntsman [1]
;
Gregg S,Nelson [48]
;
Anna V,Tinker [49]
;
Cheng-Han,Lee [50]
;
Ellen L,Goode [51]
;
Brad H,Nelson [52]
;
Susan J,Ramus [6]
;
Stefan,Kommoss [11]
;
Aline,Talhouk [1]
;
Martin,Köbel [3]
;
Michael S,Anglesio [1]
作者单位：
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.;University of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.
[1]
University of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.
[2]
Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
[3]
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.;Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
[4]
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
[5]
University of New South Wales, Adult Cancer Program, Lowy Cancer Research Centre, Sydney, Australia.;University of New South Wales, School of Women's and Children's Health, Sydney, Australia.
[6]
The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia.;Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
[7]
Medizin Campus Bodensee, Institute of Pathology, Friedrichshafen, Germany.
[8]
Department of Gynecology and Obstetrics, Medizin Campus Bodensee, Friedrichshafen, Germany.
[9]
Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
[10]
Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
[11]
University Hospital Tübingen, Institute of Pathology and Neuropathology, Tübingen, Germany.
[12]
University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany.
[13]
Department of Obstetrics and Gynecology, University Hospital Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany.
[14]
Department of Pathology, Barts Health National Health Service Trust, London, UK.
[15]
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
[16]
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
[17]
Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
[18]
Westmead Hospital, Tissue Pathology and Diagnostic Oncology, Sydney, Australia.;University of Sydney, Sydney, Australia.;Western Sydney University, Sydney, Australia.
[19]
Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.;University of Sydney, Sydney, Australia.
[20]
Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.;Westmead Hospital, Crown Princess Mary Cancer Centre, Sydney, Australia.
[21]
The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia.;Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.;University of Sydney, Sydney, Australia.;The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia.
[22]
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
[23]
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland.
[24]
Department of Propaedeutics, Physical Diagnostics and Dental Physiotherapy, Pomeranian Medical University, Szczecin, Poland.
[25]
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
[26]
Department of Metabolism, Digestion and Reproduction, Hammersmith Hospital, Imperial College London, London, UK.
[27]
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.;Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
[28]
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.;Peter MacCallum Cancer Centre, Women's Cancer Program, Melbourne, Australia.
[29]
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.;Peter MacCallum Cancer Centre, Cancer Genetics Laboratory, Research Division, Melbourne, Australia.
[30]
Division of Epidemiology and Biostatistics, The University of New Mexico, Albuquerque, NM, USA.
[31]
Cedars-Sinai Medical Center, Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Los Angeles, CA, USA.
[32]
Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
[33]
University of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA.
[34]
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, CA, USA.
[35]
Department of Obstetrics and Gynecology, Sahlgrenska Academy at Gothenburg University, Sahlgrenska Center for Cancer Research, Gothenburg, Sweden.
[36]
Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
[37]
University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.;University College London, Department of Women's Cancer, Institute for Women's Health, London, UK.
[38]
University of Innsbruck, EUTOPS Institute, Innsbruck, Austria.
[39]
University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
[40]
Department of Hematology and Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
[41]
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
[42]
Department of Histopathology, Addenbrookes Hospital, Cambridge, UK.
[43]
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
[44]
University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK.
[45]
Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
[46]
Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
[47]
Department of Oncology, Division of Gynecologic Oncology, University of Calgary, Calgary, Canada.
[48]
University of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.;Department of Medicine, University of British Columbia, Vancouver, Canada.
[49]
University of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, Canada.
[50]
Division of Epidemiology, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.
[51]
Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada.
[52]
医学主题词
脑肿瘤(Brain Neoplasms);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);加拿大(Canada);癌(Carcinoma);结直肠肿瘤(Colorectal Neoplasms);DNA结合蛋白质类(DNA-Binding Proteins);子宫内膜异位症(Endometriosis);女(雌)性(Female);人类(Humans);肿瘤综合征, 遗传性(Neoplastic Syndromes, Hereditary);核蛋白质类(Nuclear Proteins);卵巢肿瘤(Ovarian Neoplasms);预后(Prognosis);转录因子(Transcription Factors)
DOI
10.1002/path.5849
PMID
34897700
发布时间
2025-05-30
- 浏览3
The Journal of pathology
The Journal of pathology
388-401页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
